4.5 Review

Immune hemolytic anemia associated with drug therapy

期刊

BLOOD REVIEWS
卷 24, 期 4-5, 页码 143-150

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2010.06.004

关键词

Hemolytic anemia; Drugs and hemolytic anemia; Cephalosporins and hemolytic anemia; Piperacillin and hemolytic anemia; Fludarabine and hemolytic anemia; Drug antibodies

向作者/读者索取更多资源

Drug-induced immune hemolytic anemia (DIIHA) is rare; it can be mild or associated with acute severe hemolytic anemia (HA) and death. About 125 drugs have been implicated as the cause. The HA can be caused by drug-independent antibodies that are indistinguishable, in vitro and in vivo, from autoantibodies causing idiopathic warm type autoimmune hemolytic anemia (AIHA). More commonly, the antibodies are drug-dependent (i.e., will only react in vitro in the presence of the drug). The most common drugs to cause DIIHA are anti-microbials (e.g., cefotetan, ceftriaxone and piperacillin), which are associated with drug-dependent antibodies. The most common drug to cause AIHA is fludarabine. Finding out which drug is causing the problem and stopping that drug is the first approach to therapy. It is not easy to identify the drug interactions accurately in vitro; laboratories specializing in this area can be of great help. (C) 2010 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据